<?xml version="1.0" encoding="UTF-8"?>
<ref id="b11-1031835">
 <label>11.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Imagawa</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Tanaka</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Okada</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial</article-title>. 
  <source>Lancet Haematol</source>. 
  <year>2015</year>;
  <volume>2</volume>(
  <issue>12</issue>):
  <fpage>e528</fpage>â€“
  <lpage>535</lpage>.
  <pub-id pub-id-type="pmid">26686407</pub-id>
 </mixed-citation>
</ref>
